Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 29 of 29 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT04096417	Phase II	Pemigatinib	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Active, not recruiting	USA	0
NCT04233567	Phase II	Infigratinib	Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	Active, not recruiting	USA	0
NCT01004224	Phase I	Infigratinib	A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies	Completed	USA \| TUR \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| AUT \| AUS	4
NCT01868022	Phase I	Docetaxel Cisplatin + Pemetrexed Disodium GSK3052230 Carboplatin + Paclitaxel	Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling	Completed	USA \| NLD \| GBR \| ESP \| DNK \| BEL	1
NCT01975701	Phase II	Infigratinib	A Phase 2 Study of BGJ398 in Patients With Recurrent GBM	Completed	USA \| NLD \| ESP \| CHE \| BEL \| AUS	0
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Completed	USA	0
NCT02299141	Phase I	Nintedanib	Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer	Completed	USA	0
NCT02872714	Phase II	Pemigatinib	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)	Completed	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL	1
NCT03238196	Phase I	Erdafitinib + Fulvestrant + Palbociclib	Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer	Completed	USA	0
NCT03344536	Phase Ib/II	Fulvestrant + Zoligratinib	A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer	Completed	USA	0
NCT04024436	Phase II	Fulvestrant + Futibatinib Futibatinib	A Study of TAS-120 in Patients With Metastatic Breast Cancer	Completed	USA \| ITA \| GBR \| FRA \| ESP \| CAN	1
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT02925234	Phase II	Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT03767075	Phase II	Amivantamab-vmjw Futibatinib Atezolizumab	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)	Recruiting	SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT04092673	Phase Ib/II	Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin	Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin)	Recruiting	USA	0
NCT04116541	Phase II	Alectinib Regorafenib Dabrafenib + Trametinib Cabozantinib Avapritinib	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT05009992	Phase II	GDC-0084 + ONC201 ONC201 + Panobinostat	Combination Therapy for the Treatment of Diffuse Midline Gliomas	Recruiting	USA \| NZL \| NLD \| ISR \| CHE \| AUS	0
NCT05627063	Phase I	ABSK121	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT06160752	Phase I	TYRA-200	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)	Recruiting	USA	0
NCT01948297	Phase I	Zoligratinib	Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations	Terminated	USA \| ESP	3
NCT02109016	Phase II	Lucitanib	A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer	Terminated	USA \| ITA \| FRA \| ESP \| DEU	0
NCT02160041	Phase II	Infigratinib	BGJ398 for Patients With Tumors With FGFR Genetic Alterations	Terminated	USA	0
NCT02202746	Phase II	Lucitanib	A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer	Terminated	USA	0
NCT02393248	Phase Ib/II	Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Terminated	USA \| DNK	0
NCT02558348	Phase Ib/II	Anlotinib	Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)	Terminated	USA	0
NCT02608125	Phase I	PRN1371	A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma	Terminated	USA \| ESP	0
NCT02706691	Phase II	Infigratinib	Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer	Terminated	USA	0
NCT02846766	Phase II	Lenvatinib	Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling	Withdrawn	USA	0

Showing 1 to 29 of 29 entries

Filter rows:

Profile Name	FGFR1 amp
Gene Variant Detail	FGFR1 amp (no effect)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR1 Inhibitor GSK3052230

Molecular Profile Detail

Contact

Filtering

Sorting